Topical ketorolac tromethamine in the reduction of adverse effects of laser in situ keratomileusist.
OBJECTIVE
To evaluate whether topical ketorolac tromethamine can reduce the adverse effect of laser in situ keratomileusis (LASIK).


METHODS
A prospective randomized controlled clinical study.


METHODS
Nineteen patients who underwent bilateral simultaneous LASIK performed at Siriraj Hospital.


METHODS
Patients received two drops of ketorolac tromethamine in one eye immediately after surgery.


METHODS
Symptoms of tearing, photophobia, foreign body sensation and pain were evaluated at 30 minutes, 6 hours and 24 hours.


RESULTS
There was no statistically significant difference in symptoms at 30 minutes. At 6 and 24 hours, ketorolac-treated eyes had significantly fewer symptoms compared to non-treated eyes.


CONCLUSIONS
Ketorolac tromethamine reduces some unfavorable symptoms within the first 24 hours after LASIK.
Kosrirukvongs
P
P
Department of Ophthalmology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Prabhasawat
P
P
Srivannaboon
S
S
Pornpanich
K
K
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D001251:Astigmatism / Q000601:surgery*; D005260:Female; D006801:Humans; D020731:Keratomileusis, Laser In Situ / Q000009:adverse effects*; D020911:Ketorolac Tromethamine / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009216:Myopia / Q000601:surgery*; D010147:Pain Measurement; D011446:Prospective Studies
D000894:Anti-Inflammatory Agents, Non-Steroidal; D020911:Ketorolac Tromethamine